Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Benzinga · 3d ago
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.